uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarction
Show others and affiliations
2006 (English)In: European Heart Journal, ISSN 0195-668X, E-ISSN 1522-9645, Vol. 27, no 4, 419-426 p.Article in journal (Refereed) Published
Abstract [en]

AIMS: To demonstrate the feasibility and clinical utility of developing dynamic risk assessment models for ST-segment elevation myocardial infarction (STEMI) patients. METHODS AND RESULTS: In 6066 STEMI patients enrolled in the Assessment of the Safety and Efficacy of a New Thrombolytic-3 (ASSENT-3) trial with complete electrocardiographic data, we assessed the probability of 30-day mortality over the following forecasting periods beginning at day 0 (baseline), 3 h, day 2, and day 5 using multiple-logistic regression. These models were validated and simplified in independent samples of 1622 similar fibrinolytic-treated patients from the ASSENT-3 PLUS trial and in 814 STEMI patients undergoing primary percutaneous coronary intervention in the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. The discriminatory power of these predictive models, from baseline to day 5, was excellent (c-statistics 0.80 to 0.87); and their predictive ability was supported by strong gradients in mortality outcomes as the risk score increased. Dynamic modelling also provided information on the change in prognosis over time which may be used to advise more appropriate therapeutic decisions, e.g. the identification of high-risk patients for possible co-interventions. CONCLUSION: Dynamic modelling for STEMI patients enhances the risk assessment and stratification and should provide valuable ongoing guidance for their management.

Place, publisher, year, edition, pages
2006. Vol. 27, no 4, 419-426 p.
Keyword [en]
Adult, Aged, Angioplasty; Transluminal; Percutaneous Coronary/methods, Feasibility Studies, Female, Humans, Male, Middle Aged, Models; Biological, Myocardial Infarction/*mortality/therapy, Predictive Value of Tests, Prognosis, Randomized Controlled Trials, Regression Analysis, Risk Assessment/methods/standards, Thrombolytic Therapy/methods
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:uu:diva-24434DOI: 10.1093/eurheartj/ehi700PubMedID: 16407373OAI: oai:DiVA.org:uu-24434DiVA: diva2:52208
Available from: 2007-02-05 Created: 2007-02-05 Last updated: 2017-12-07Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=16407373&dopt=Citation

Authority records BETA

Wallentin, Lars

Search in DiVA

By author/editor
Wallentin, Lars
By organisation
Department of Medical Sciences
In the same journal
European Heart Journal
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 372 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf